- Report
- February 2024
- 70 Pages
United Kingdom
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
France
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
United States
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Spain
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Iran
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Russia
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Australia
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
China
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Japan
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 70 Pages
India
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 90 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2023
- 150 Pages
North America
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4323EUR$4,750USD£3,706GBP

Victoza is a prescription medication used to treat obesity. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by stimulating the release of insulin and suppressing appetite. It is typically prescribed to people who are overweight or obese and have not been able to lose weight through diet and exercise alone. Victoza is usually taken once a day, and it can be used in combination with other anti-obesity drugs.
Victoza is one of several anti-obesity drugs available on the market. Other drugs in this class include Saxenda, Contrave, and Belviq. These drugs work by targeting different pathways in the body to help reduce appetite and promote weight loss.
The market for anti-obesity drugs is highly competitive, with many companies vying for a share of the market. Some of the major players in this market include Novo Nordisk, Orexigen Therapeutics, Arena Pharmaceuticals, Vivus, and Eisai. Show Less Read more